Company* |
University/ |
Type Of |
Product Area |
Details (Date) |
Accentia Bio- |
Mayo Foundation for MedicalResearch and Education |
Amended licenseagreement |
Accentia got rights to products for treatingsymptoms associated with chronic sinusitis |
Exclusive, worldwide deal covers nonprescription products thatact by suppressing noninvasive fungi in mucus of patients (8/28) |
Accentia Bio- |
Mayo Foundation for MedicalResearch and Education |
Option agreement |
They extended until December 2007 a dealthat gives Accentia certain options |
Accentia can license intranasal antifungals agents for chronicsinusitis; the new deadline is beyond the expected NDA filingdate for Accentia's SinuNase (7/24) |
Alfacell |
West German Cancer Center |
Collaboration |
Deal to develop a fusion protein fortreating non- Hodgkin's lymphoma |
The fusion protein consists of Onconase and a humanized anti-CD22 monoclonal antibody; terms were not disclosed (7/11) |
Alnylam |
University of TexasSouthwestern Medical Center |
Collaboration |
Deal to evaluate new approaches forreducing LDL cholesterol levels |
They will test RNAi therapeutics against proprotein convertasesubtilisn/kexin type 9; terms were not disclosed (7/17) |
Asuragen Inc.* |
Max Planck Society(Germany) |
License agreement |
Asuragen got rights to use more than 200microRNA sequences in diagnostic applications |
The license is semi-exclusive; terms of the deal were not disclosed (7/27) |
Asuragen Inc.* |
Rockefeller University |
License agreement |
Asuragen got diagnostic rights tomicroRNA sequences from Rockefeller |
The license is semi-exclusive; terms of the deal were not disclosed (7/26) |
BioDiem Ltd. |
Centers for Disease Controland Prevention |
CRADA |
Deal for development of a live, attenuatedcell culture vaccine against the H5N1 strainof avian influenza and Nobilon (unit of Akzo Nobel NV) |
BioDiem and Nobilon previously entered a licensing deal covering BioDiem's intranasal flu vaccine technology, which is the subject of the CRADA (8/30) |
BioE Inc.* |
University of Newcastle uponTyne (UK) |
Collaboration |
Will work on isolating rare stem cells with therapeutic potential from cord blood |
They will use BioE's PrepaCyte cell- isolation platform to developa library of cells, which then could be used for research anddrug discovery purposes (5/30) |
BioLineRx |
Hebrew University ofJerusalem |
License agreement |
BioLineRx got rights to BL-3020, an orallyavailable peptide for treating obesity |
Terms of the exclusive deal were not disclosed; trials in humansare expected in 2008 (7/17) |
Biosite Inc. |
Hopitaux Universitairesde Geneve (Switzerland) |
Collaboration |
To identify and validate protein-based diseasebiomarkers for kidney injury |
Biosite will get rights to develop diagnostic tests using biomarkers discovered by HUG; terms of the deal were not disclosed(8/23) |
Callisto |
University of Texas M.D.Anderson Cancer Center |
Sponsored researchagreement |
Work will support development of Callisto's Degrasyn class of cancercompounds |
Callisto recently licensed the class of compounds, formerlyreferred to as tyrphostins, from the cancer center; terms werenot disclosed (6/15) |
Cepheid Inc. |
Foundation for InnovativeDiagnostics (Switzerland) |
Collaboration |
Deal to develop a rapid molecular diagnostictest for tuberculosis |
Cepheid will work with the University of Medicine and Dentistryof New Jersey on the test, which will be designed to run on Cepheid's GeneXpert System (5/23) |
Chemokine |
Fred Hutchinson |
Agreement compound CTCE-0214 |
Deal to study the company's hematological support were not disclosed (6/21) |
The cancer center will perform a series of preclinical tests forChemokine; terms of the deal |
Chimerix Inc.* |
University of Michigan |
Acquisition |
Chimerix acquired a library of chemical leadcompounds |
The compounds are designed against antiviral and oncologytargets; terms of the deal were not disclosed (5/24) |
CombinatoRx |
Cystic Fibrosis FoundationTherapeutics Inc. |
Collaboration |
Deal to discover and develop CF therapeuticsbuilt from synergistic drug combinations |
CombinatoRx can receive up to $13.8M in research expenses, andmilestone payments; it will fund most expenses through Phase IIatrials and own resulting drugs; CFFT would get royalties onresulting sales (6/1) |
CytRx Corp. |
ALS Charitable Remainder Trust |
Royalty agreement |
Deal to help fund CytRx's arimoclomolfor treating amyo- trophic lateral sclerosis |
CytRx gets $24.5M to help fund development; the ALS Trustwould receive a royalty of 1% on resulting sales (8/29) |
DNAPrint |
Beth Israel DeaconessMedical Center |
Sponsoredresearchagreement |
For study of a more potent, longer-actingform of the anemia agent erythropoietin |
Work will focus on PT-401, which DNAP previously licensed from the medical center; BIDMC will get $600,000 for the work (7/18) |
Edison |
CHDI Inc. |
Collaboration |
Deal to develop analogues of CoQ(10)for use in Huntington's disease |
The agents will be selectively targeted to reach the brain andaddress the mitochondrial component of HD; Edison gets rightsto resulting therapeutics (8/1) |
Epigenomics |
Stanford University |
Collaboration |
They will investigate the use of DNA methylation markers in detecting colorectal cancer |
A study, co-funded by Roche Diagnostics, will be carried outwith the Molecular Imaging Program at Stanford (6/8) |
Evolutec |
Case Western ReserveUniversity |
Collaboration |
Case Western will conduct preclinicalstudies of rEV576, Evolutec's candidate for myasthenia gravis |
Evolutec will provide product and Case Western will providethe research funding; further terms were not disclosed (5/24) |
Evotec AG |
CHDI Inc. |
Partnership |
Evotec technologies will be used indiscovery programs for Huntington's disease |
The parties have signed four deals in the area since March2006; terms were not disclosed (8/10) |
Exiqon A/S* |
Max Planck Society (Germany)and Rockefeller University |
License agreements |
Exiqon got rights to use microRNA sequences in diagnostic applications |
The licenses are semi-exclusive; terms of the separate deals were not disclosed (7/27) |
454 Life |
Max Planck Institute forEvolutionary Anthropology(Germany) |
Collaboration |
Deal to sequence the complete Neandertalgenome |
The effort focused on the human relative will use sequencing technology from 454 and a grant from Max Planck (7/20) |
Genedata AG* |
Infections and CancerConsortium |
Collaboration |
Genedata will provide research informaticsfor the consortium |
The consortium was provided €12.6M of funding by the European Commission to discover the role of chronic infection inthe development of cancer (6/27) |
Gene Logic |
U.S. FDA |
Agreement |
Deal gives the FDA access to certain Gene Logic genomics data and software |
The products will help the FDA evaluate voluntary genomics data submissions; terms of the deal were not disclosed (8/10) |
Geron Corp. |
University of Edinburgh (UK) |
Collaboration |
Deal for preclinical studies of three cell types from human embryonic stem cells |
The focus is hepatocytes for treating liver failure, and osteoblasts and chondrocytes for musculoskeletal disorders (8/7) |
GliaGen LLC* |
Wayne State University |
License agreement |
Allied Minds Inc. and Wayne State formed GliaGen to develop neurodegenerative technologies |
The technology was developed at the university; GliaGen also will support further research at Wayne State (8/23) |
Hemispherx |
Vanderbilt University |
License agreement |
Hemispherx got rights to the compound DOGS for delivery of DNA to interiors of cells |
The company plans to use the technology in creation of a vaccine platform; terms of the deal were not disclosed (8/29) |
HepaLife |
Michigan State University |
License agreement |
HepaLife got rights to develop new cell culture-based influenza vaccines |
MSU is entitled to milestone and royalty payments; HepaLife's rights are worldwide (7/10) |
Immtech |
University of North Carolina |
Agreement |
Deal focused on development of Immtech's pafuramidine maleate to treat African sleeping sickness |
A UNC-led consortium will provide additional funding and support for development of the oral agent, under an expansion of an earlier agreement (5/23) |
ImmuneRegen |
Defense Medical & Environmental Research Institute (Singapore) |
Agreement |
Deal to study IR's Viprovex on acute melioidosis |
The compound will be studied in mouse models for treating the infectious disease; terms were not disclosed (7/31) |
ImmuneRegen |
National Institute of Allergy and Infectious Diseases |
Agreement |
The NIAID will fund and conduct a preclinical antimicrobial evaluation of ImmuneRegen's Viprovex |
The compound will be studied for potential use as a treatment for certain infectious respiratory diseases, including influenza, measles and SARS (6/28) |
Innate Pharma |
Institut Gustave-Roussy (France) |
Collaboration |
Deal covering research into the manipulation of Toll-like receptors |
The focus of the effort is treatment of cancer; terms were not disclosed (6/19) |
Innovive |
KTB Tumorforschungs GmbH (Germany) |
License agreement |
Innovive got rights to DOXO-EMCH (now INNO-206), a doxorubicin prodrug |
A Phase II trial in solid tumors was being planned; terms of the worldwide deal were not disclosed (8/22) |
Interleukin |
Catholic University (Italy) |
Collaboration |
To study interleukin-1 genetic variations and their possible association with stroke |
They will analyze genetic material from 460 subjects in Italy (6/19) |
Invitrogen |
Human Proteome Organization |
Collaboration |
They plan to advance proteomic research through a number of initiatives |
Invitrogen will support HUPO efforts to develop new proteomic standards, products and processes; terms of the deal were not disclosed (7/11) |
Jerini AG |
Mount Sinai School of Medicine |
Collaboration |
Deal to discover B-cell epitopes for use in the area of food allergies |
The goal is to develop vaccines and personalized diagnostics; Jerini subsidiary JPT Peptide Technologies GmbH will work with Mount Sinai (7/24) |
Lentigen |
University of Pennsylvania |
Collaboration |
Research deal to develop cancer drugs |
The initial research focus is T-cell signaling pathways; Lentigen gets rights to resulting products (7/27) |
Lentigen |
U.S. Army Edgewood Chemical Biological Center |
CRADA |
They will work on research programs in the area of lentiviral vectors |
Research will focus on using the vectors in vaccine development, therapeutics and biodefense applications; terms of the deal were not disclosed (5/30) |
Lentigen |
University of Pennsylvania in Philadelphia |
License agreement |
Lentigen got exclusive, worldwide rights to to lentiviral vector technology |
The technology is used to deliver genes or RNAi into cells; terms of the deal were not disclosed (5/19) |
Life Science |
Ludwig Institute for Cancer Research |
Agreement |
LSP got rights to three monoclonal antibodies, targeting cancer and autoimmune diseases |
Terms of the deal were not disclosed (6/1) |
LifeScreen Inc.* |
University of Missouri- Columbia |
License agreement |
Allied Minds Inc. and the university formed LifeScreen to develop breast cancer screening technology |
UM gets an equity position in the new company, and royalties on resulting sales; LifeScreen also will support research at the university (8/24) |
MedImmune |
National Institute of Allergy and Infectious Diseases |
CRADA |
Deal to develop live, attenuated intranasal vaccines against pediatric respiratory viruses |
The focus is on respiratory syncytial virus, parainfluenza virus types 1-3 and metapneumovirus (6/29) |
MerLion |
Institute of Chemical and Engineering Sciences (Singapore) |
Collaboration |
To develop molecules, based on naturally derived compounds, for treating cancers |
ICES will design and synthesize compounds, which may be further modified and optimized by MerLion; terms were not disclosed (5/31) |
Nektar |
University of Alabama in Huntsville |
Settlement agreement |
UAH agreed to dismiss all claims related to the Nektar PEGylation patent |
Nektar is paying the university $15M up front and $1M per year for 10 years (7/7) |
Nostrum |
Institute of Microbial Technology (India) |
License agreement |
Nostrum got exclusive rights to a protein named Clot Specific Streptokinase |
The clot-buster will be developed with Symmetrix Pharmaceuticals Inc., an affiliate of Nostrum; terms were not disclosed (7/27) |
NuPathe Inc.* |
University of Pennsylvania |
License agreement |
NuPathe got rights to LAD long-acting delivery technology |
The technology provides for one- to three-month dosing; terms of the exclusive, worldwide deal were not disclosed (8/16) |
OctoPlus |
Leiden University Medical Center (the Netherlands) |
License agreement |
OctoPlus got full rights to OP- 45 through an expansion of an existing license agreement |
The product is in clinical development for treating chronic middle ear infections; LUMC is entitled to up-front and royalty payments in the deal (7/5) |
Pharsight |
FDA Center for Drug Evaluation and Research |
CRADA |
Pharsight will provide software tools that the FDA will use to review clinical trial data |
The focus is on pharmacology and clinical safety reviews; terms were not disclosed (6/7) |
PhytoMedical |
Iowa State University Research Foundation Inc. |
License agreement |
PhytoMedical got rights to compounds derived from type A-1 poly-phenols, for treating Type II diabetes |
ISURF is entitled to an up-front license fee, as well as potential milestone and royalty payments (6/13) |
Potentia |
University of Pennsylvania |
License agreement |
Potentia got rights to the Compstatin class of complement- inhibiting peptides for treatment of ocular diseases |
Initial preclinical programs will be in age- related macular degeneration; terms of the exclusive deal were not disclosed (8/8) |
Predix |
Cystic Fibrosis Foundation Therapeutics Inc. |
Collaboration expansion |
They are working on two programs focused on identifying compounds for CF |
Predix is entitled to an additional $3.5M in research funding and milestone payments under the expansion (8/3) |
Proximagen |
Northwestern University |
License agreement |
Proximagen got rights to a platform of drug candidates for treating central nervous system disorders |
The university is entitled to an up-front payment and potential milestone and royalty payments; Proximagen's rights are exclusive (5/22) |
PTC |
Spinal Muscular Atrophy Foundation |
Collaboration |
To use PTC's GEM technology to identify and develop small- molecule drugs for SMA |
PTC is entitled to up to $1.6M in milestone payments in the deal (6/7) |
Radius* |
University of Illinois |
License agreement |
Radius got rights to several new classes of estrogen receptor-eta- selective compounds |
Radius plans to develop the compounds for endometriosis and other inflammatory diseases under the exclusive deal; terms were not disclosed (8/7) |
Raptor |
Stanford School of Medicine |
Collaboration |
Deal to study the utility of Raptor's Receptor-Associated Protein vectors |
They will be evaluated as transporters of intravenous therapeutics across the blood-brain barrier (8/10) |
Rosetta |
Max Planck Society (Germany) |
License agreement |
Rosetta got access to hundreds of human microRNA sequences for diagnostic applications |
The license is semi-exclusive; terms of the deal were not disclosed (7/27) |
Rosetta Genomics |
Rockefeller University |
License agreement |
Rosetta got access to nearly 180 proprietary microRNAs |
Rosetta will use the microRNAs to advance R&D programs; the university gets an up-front fee, maintenance fees and royalties on any resulting sales (6/14) |
Salix |
Cedars-Sinai Medical Center |
License agreement |
Salix got rights to methods to diagnosis and treat irritable bowel syndrome and other disorders |
Salix got exclusive rights to rifaximin, which it markets as Xifaxan; CSMC gets a license fee, and would get royalties on sales for IBS (7/5) |
Sonus |
Cancer and Leukemia Group B Foundation |
Agreement |
Sonus acquired data from a Phase III trial of Taxol in metastatic breast cancer |
Sonus is developing a formulation of Taxol, and may use the data in support of regulatory submissions (7/5) |
Stem Cell |
University of Nice (France) |
License agreement |
SCS got rights to human multi-potent adipocyte-derived cells |
SCS can use the cells for drug discovery in the areas of obesity and osteoporosis (7/25) |
Targeted |
International Aids Vaccine Initiative |
Collaboration and license agreement |
Deal to develop and market HIV/AIDS vaccines for the developing world; it supercedes a deal signed in 2000 |
Targeted Genetics will continue to receive funding from IAVI; Columbus Children's Research Institute and The Children's Hospital of Philadelphia are partners in the effort (6/28) |
Tigris |
National Institutes of Health |
License agreement |
Tigris got exclusvie rights to develop an aminoflavone prodrug (AFP-464) for cancer |
The product is in Phase I trials; the NIH is entitled to milestone and royalty payments (7/17) |
Tigris |
H. Lee Moffitt Cancer Center & Research Institute, Yale University and the University of South Florida |
License agreements |
Tigris got exclusive rights to several small molecules for cancer, including GFB-204 and GGTI-2418 |
Tigris plans to start human trials on the lead compounds in 2007; the nonprofit organizations are entitled to milestone and royalty payments (7/12) |
Transgene |
National Cancer Institute |
CRADA |
Deal to develop melanoma treatments based on tumor- associated antigens identified by the NCI |
Transgene and the NCI will evaluate candidate vaccines, with the objective to assess the boosting effect of the vaccination on lymphocyte activity (6/21) |
WEX Pharmaceuticals |
Children's Hospital Boston |
License agreement |
WEX got rights to drugs containing Tetrodotoxin for use in prolonged local anesthesia |
The parties signed a term sheet, details of which were not disclosed (8/10) |
Zygogen LLC* |
University of Minnesota in zebrafish |
License agreement |
Zygogen got rights to use morpholino antisense technology |
The university is entitled to license and royalty payments; the license is exclusive (7/13) |
|
| ||||
Notes: | ||||
This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers. | ||||
* Denotes privately held company. | ||||
@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted. | ||||
CRADA = Cooperative Research and Development Agreement. | ||||
Unless otherwise noted, shares are traded on the Nasdaq exchange. | ||||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; | ||||
FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||
